Saturday 17 October 2026 Export PBYI’s income statement to Excel — free account

Puma Biotechnology, Inc.

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%

Follow PBYI

Alert me

Market cap: $543.0M
P/E: 18.2×
Fwd P/E: 24.2×
Dividend yield: —
F-score: 8/9
Altman Z: −4.16
Beneish M: −2.06
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.12

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	3	—	—	—	—	5	3	—	2	—

Insider Ownership 21.32%

Capital & Financial Ratios $m

Market Cap 543.04

Revenue 231.24

Net Income 26.72

Free Cash Flow 41.15

Net Debt (93.90)

Current Ratio 2.91

Debt/Equity 0.00

P/E ratio 18.20

Fwd P/E 24.20

P/S ratio 2.17

P/B ratio 3.61

Past 5Y EPS Growth —

This Y EPS Growth (37.70%)

Next Y EPS Growth (47.37%)

Next Y revenue growth (1.04%)

Next 5Y EPS Growth (9.64%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 74.45%

10-year low 10-year high

P/S against its own 10 years 88.44%

10-year low 10-year high

P/B against its own 10 years 24.41%

10-year low 10-year high

EV/Sales against its own 10 years 84.56%

10-year low 10-year high

EV/FCF against its own 10 years 67.97%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	96	101	100	94
Receivables	48	32	54	34
Inventory	7	9	6	13
Other	1	0	0	0
	156	148	163	145

	2023	2024	2025	Q'26
Payables	7	6	5	3
ST’ Debt	34	45	23	—
Other	1	3	2	1
	99	96	81	50

Compound Annual Growth %

	10y	5y	3y
Sales	—	0.29%	0.05%
Cash Flow	0.00%	122.13%	0.00%
Earnings	0.00%	0.00%	2,396.29%
Book Value	(4.47%)	0.00%	82.03%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	45	57	—	—	—
’25	46	52	54	75	228
’24	44	47	81	59	230
’23	53	55	56	72	236
’22	46	60	57	66	228
’21	98	53	46	55	253
’20	51	71	51	53	225

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	2	—	—	—
’25	4	14	10	14	42
’24	11	1	11	16	39
’23	3	3	11	10	27
’22	(27)	(14)	17	8	(16)
’21	16	0	10	(5)	21
’20	(12)	16	2	(6)	1

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	15	2	—	—	—
’25	4	14	10	14	42
’24	11	1	11	16	39
’23	(10)	3	11	10	14
’22	(27)	(14)	17	1	(23)
’21	16	0	10	(5)	21
’20	(12)	6	2	(6)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.07)	0.16	—	—	—
’25	0.06	0.12	0.17	0.26	0.61
’24	(0.10)	(0.09)	0.41	0.39	0.62
’23	0.03	0.05	0.12	0.26	0.45
’22	(0.08)	0.21	(0.01)	(0.12)	0.00
’21	0.40	(0.13)	(1.09)	0.10	(0.72)
’20	(0.43)	0.08	(0.79)	(0.38)	(1.52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	19.74	28.35	17.60	6.26	5.50	2.78	1.60	2.13	2.23	2.58	Analyst estimates 2026–2028 Powerpack
	High	77.99	136.90	101.50	43.90	15.00	14.14	5.16	4.89	7.73	6.27
People
People	Employees	160	318	272	269	267	196	192	185	172	179
	Revenue/emp, $m	0.00	0.09	0.92	1.01	0.84	1.29	1.19	1.27	1.34	1.28
Income, $m
Income, $m	Revenue	—	28	251	272	225	253	228	236	230	228
	Gross margin, %	0.00	79.87	86.21	86.48	82.51	74.84	75.84	73.40	72.06	74.53
	EBT	(276)	(292)	(114)	(76)	(60)	(29)	0	23	24	36
	EBT margin, %	0.00	(1,054.56)	(45.24)	(27.75)	(26.56)	(11.38)	0.20	9.62	10.46	15.67
	Net income	(276)	(292)	(114)	(76)	(60)	(29)	0	22	30	31
	Depreciation	1	3	7	8	10	11	10	12	12	11
Per share, $
Per share, $	Revenue	0.00	0.74	6.62	7.02	5.69	6.23	5.10	5.00	4.74	4.57
	Earnings	(8.29)	(7.85)	(2.99)	(1.95)	(1.52)	(0.72)	0.00	0.46	0.62	0.62
	Cash flow	(4.26)	(4.64)	(0.64)	0.58	0.02	0.51	(0.35)	0.57	0.80	0.84
	Capex	(0.22)	(1.36)	(0.02)	(0.01)	(0.25)	0.00	(0.16)	(0.27)	0.00	0.00
	Free cash flow	(4.47)	(6.00)	(0.65)	0.57	(0.23)	0.51	(0.51)	0.30	0.80	0.83
	Book value	6.30	1.43	0.90	0.45	(0.15)	(0.06)	0.48	1.13	1.89	2.61
	Shares, m	33	37	38	39	40	41	45	47	49	50
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	1,966.67	9.85	5.00	9.44
	P/S	—	0.00	3.08	1.25	1.80	0.49	0.81	0.91	0.64	1.30
	P/B	—	64.61	22.51	19.43	0.00	0.00	8.54	4.00	1.61	2.28
	EV/Sales	—	0.00	3.02	1.16	1.79	0.53	0.90	0.92	0.50	1.01
	EV/FCF	—	(19.73)	(30.69)	14.71	(41.98)	12.94	(8.88)	15.14	4.35	7.91
Cash, $m
Cash, $m	Operating cash flow	(142)	(172)	(24)	22	1	21	(16)	27	39	42
	Capex	(7)	(50)	(1)	0	(10)	—	(7)	(13)	0	0
	Free cash flow	(149)	(223)	(25)	22	(9)	21	(23)	14	39	42
Balance, $m
Balance, $m	Working capital	199	48	136	75	32	30	57	57	52	81
	Total debt	—	48	152	98	98	101	102	100	67	23
	Net debt	(229)	(33)	(14)	(23)	(4)	10	21	4	(34)	(77)
	Shareholders’ equity	210	53	34	17	(6)	(2)	22	53	92	130
Returns, %
Returns, %	ROA	(112.06)	(139.59)	(53.49)	(30.60)	(25.04)	(12.37)	0.00	9.54	13.64	14.48
	ROIC	0.00	(910.03)	(284.82)	0.00	0.00	11.10	34.49	35.69	33.25	43.78
	ROE	(132.75)	(221.91)	(259.28)	(292.05)	(1,042.29)	693.73	0.02	57.54	41.60	27.97

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)	Compare
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%
DRUG Bright Minds Biosciences Inc.	$534.7M	— (loss-making)	—	—	n/m	−124.63% (below 0%: shrinking)	0.00%	0.00%	Compare
FTH Faeth Therapeutics, Inc.	$532.3M	— (loss-making)	—	—	n/m	−174.24% (below 0%: shrinking)	0.00%	0.00%	Compare
CTMX CytomX Therapeutics, Inc.	$525.1M	— (loss-making)	— (loss-making)	−92.40% (below 0%: shrinking)	n/m	−14.50% (below 0%: shrinking)	100.00%	(1,677.08%)	Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR	$524.8M	— (loss-making)	— (loss-making)	−7.53% (below 0%: shrinking)	n/m	−31.52% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$540.1M	—	—	−17.29%	—	−56.05%	53.61%	0.00%

All 614 Biotechnology stocks →

Puma Biotechnology, Inc. (PBYI) key facts

Concern: Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.
Puma Biotechnology, Inc. (PBYI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PBYI traded at $9.83, a market capitalization of $543.0 million.
Return on equity was 28.0% and debt-to-equity 0.00.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is −4.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.